Literature DB >> 10967570

Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy?

S Chakrabarti1, K E Collingham, C D Fegan, D Pillay, D W Milligan.   

Abstract

Adenovirus has been recognised as an important pathogen in BMT recipients, especially in patients with GVHD and those receiving T cell-depleted allografts. We report adenovirus infections from an ongoing surveillance study in four patients after a non-myeloablative transplant and their improved outcome following withdrawal of immunosuppression in two patients and donor lymphocyte infusion for relapsed disease in the others. We discuss the control of adenovirus infections following immune manipulations and the feasibility of adoptive immunotherapy for post-transplant adenovirus infections.

Entities:  

Mesh：

Year:  2000        PMID： 10967570     DOI： 10.1038/sj.bmt.1702508

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  14 in total

Review 1.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Molecular detection and quantitative analysis of the entire spectrum of human adenoviruses by a two-reaction real-time PCR assay.

Authors:  K Ebner; M Suda; F Watzinger; T Lion
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

Review 3.  How I treat adenovirus in hematopoietic stem cell transplant recipients.

Authors:  Caroline A Lindemans; Ann M Leen; Jaap Jan Boelens
Journal:  Blood       Date:  2010-09-13       Impact factor: 22.113

4.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

Review 5.  Adenoviruses in immunocompromised hosts.

Authors:  Marcela Echavarría
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

6.  Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy.

Authors:  Bianca Heemskerk; Louise A Veltrop-Duits; Tamara van Vreeswijk; Monique M ten Dam; Sebastiaan Heidt; Rene E M Toes; Maarten J D van Tol; Marco W Schilham
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection.

Authors:  Kirsten Marie Williams; Allison L Agwu; Alix A Dabb; Meghan A Higman; David M Loeb; Alexandra Valsamakis; Allen R Chen
Journal:  J Pediatr Hematol Oncol       Date:  2009-11       Impact factor: 1.289

8.  Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection.

Authors:  L Lenaerts; H Kelchtermans; L Geboes; P Matthys; E Verbeken; E De Clercq; L Naesens
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

9.  PCR diagnostics and monitoring of adenoviral infections in hematopoietic stem cell transplantation recipients.

Authors:  Iwona Bil-Lula; Marek Ussowicz; Blanka Rybka; Danuta Wendycz-Domalewska; Renata Ryczan; Ewa Gorczyńska; Krzysztof Kałwak; Mieczysław Woźniak
Journal:  Arch Virol       Date:  2010-09-17       Impact factor: 2.574

Review 10.  The challenge of respiratory virus infections in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh
Journal:  Br J Haematol       Date:  2008-09-10       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.